Saturday, 18 May 2024


Calidi Biotherapeutics Reports First Quarter 2024 Operating and Financial Results By

MBIA Inc. Reports First Quarter 2024 Financial Results By

Three upcoming posters, including an update from ongoing Phase 1 trial of Calidi’s CLD-101 program, to be presented at 2024 ASCO Annual Meeting

Presented new data on the mechanisms of action of Calidi’s novel immunotherapies at the AACR Annual Meeting

Unveiled RTNova systemic platform allowing for ease of administration and ability to target multiple tumor types

Completed $6.1 million public offering

SAN DIEGO–(BUSINESS WIRE)–Calidi Biotherapeutics Inc. (NYSE American: CLDI) (Calidi), a clinical-stage biotechnology company developing a new generation of targeted virotherapies, today reported its first quarter 2024 operating and financial results and reviewed recent business highlights.

Calidi’s current focus is on raising additional capital and implementing continued cost cutting measures in order to advance our promising pipeline of novel immunotherapies designed to successfully target and eliminate solid tumors across the body. We plan to present three posters at ASCO including an update from our ongoing trial with City of Hope for recurrent high-grade glioma, said Allan Camaisa, CEO and Chairman of the Board at Calidi Biotherapeutics. In parallel to our clinical progress, Calidi has strengthened our preclinical programs through our powerful R&D engine, unveiled our novel systemic delivery platform to target diverse tumor types, and executed a capital raise to strengthen our balance sheet. We believe these efforts will help propel the company through important milestones including an interim clinical update from our ongoing Phase 1 trial and the initiation of the Phase 1 trial with Northwestern (NASDAQ:) University anticipated in the third quarter of 2024, subject to additional capital being raised.

3rd party Ad. Not an offer or recommendation by See disclosure here or
remove ads

First Quarter 2024 and Recent Corporate Developments

  • Announced upcoming poster presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The posters will include an update from the Phase 1 trial in collaboration with City of Hope for CLD-101 in recurrent high-grade glioma. Additional posters will focus on preclinical data from the company’s RTNova (CLD-400) and CLD-201 platforms.
  • Presented new data at the American Association for Cancer Research Annual Meeting (AACR) supporting CLD-101 and CLD-201’s first-in-class use of stem cells to protect and potentiate antitumor virotherapies. The results of experiments, conducted in…

Click Here to Read the Full Original Article at All News…